IIM
ELVN icon

INTECH Investment Management’s Enliven Therapeutics ELVN Stock Holding History

INTECH Investment Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$614K Buy
12,090
+1,482
+14% +$62.9K 0.01% 1255
2026
Q1 		$416K Sell
10,608
-6,121
-37% -$170K ﹤0.01% 1426
2025
Q4 		$258K Buy
16,729
+2,256
+16% +$44.9K ﹤0.01% 1844
2025
Q3 		$296K Sell
14,473
-29
-0.2% -$585 ﹤0.01% 1827
2025
Q2 		$291K Sell
14,502
-5,601
-28% -$106K ﹤0.01% 1880
2025
Q1 		$396K Buy
20,103
+3,781
+23% +$81.4K ﹤0.01% 1747
2024
Q4 		$367K Buy
+16,322
New +$423K ﹤0.01% 1732

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

INTECH Investment Management's ELVN Position: Q2 2026 in Review

INTECH Investment Management increased its Enliven Therapeutics (ELVN) stake by 14% in Q2 2026, buying an estimated $62.9K and bringing the position to 12,090 shares worth $614K. The position accounts for 0.01% of the portfolio, ranked #1255.

INTECH Investment Management first reported a position in ELVN in Q4 2024 and has held it in 7 quarters since. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • INTECH Investment Management held 12,090 shares of Enliven Therapeutics worth $614K as of Q2 2026.
  • INTECH Investment Management bought 1,482 Enliven Therapeutics shares in Q2 2026, an estimated $62.9K.
  • Enliven Therapeutics made up 0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1255 holding.
  • INTECH Investment Management first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.